23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › BioMarin Pharmaceutical Inc. › 2025-2026

BioMarin Pharmaceutical Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BioMarin Pharmaceutical Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 13Ballot items
  • 510Asset managers, any item
  • 7,512Fund votes
  • June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 13 items on BioMarin Pharmaceutical Inc.’s Form 8-K, filed June 4, 2026: 10 elected · 3 approved.

Dissent

Notable dissent: 1 director (11.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BioMarin Pharmaceutical Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by BioMarin Pharmaceutical Inc.

These tallies are BioMarin Pharmaceutical Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BioMarin Pharmaceutical Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Elizabeth M. Anderson 152,826,85511,325,40041,995 --11,619,042 93%Elected—
Elect Director: Barbara W. Bodem 162,832,241796,989565,020 --11,619,042 99.5%Elected—
Elect Director: Ian T. Clark 144,380,10119,160,530653,619 --11,619,042 88%Elected—
Elect Director: Athena Countouriotis 162,326,0651,823,39944,786 --11,619,042 99%Elected—
Elect Director: Willard Dere 161,112,6062,973,541108,103 --11,619,042 98%Elected—
Elect Director: Mark J. Enyedy 161,113,3253,032,04048,885 --11,619,042 98%Elected—
Elect Director: Alexander Hardy 163,115,6331,028,50650,111 --11,619,042 99.4%Elected—
Elect Director: Maykin Ho 160,849,4373,300,11744,696 --11,619,042 98%Elected—
Elect Director: Robert J. Hombach 160,262,5013,342,524589,225 --11,619,042 98%Elected—
Elect Director: Timothy P. Walbert 158,544,6835,554,11695,451 --11,619,042 97%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy 170,867,3354,850,52695,431 ---- 97%Approved—
3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement 142,742,80021,287,767163,683 --11,619,042 87%Approved—
4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment 158,561,8675,480,380152,003 --11,619,042 97%Approved—

Source: BioMarin Pharmaceutical Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the BioMarin Pharmaceutical Inc. 2025-2026 meeting

510 asset managers disclosed a vote on at least one BioMarin Pharmaceutical Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alexander Hardy

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 163,115,633AGAINST: 1,028,506

Prior year: 99.4% for (May 20, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Alexander Hardy

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Alexander Hardy”): 163,115,633 for, 1,028,506 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 80,242,958 for, 4,676 against, 30,100 abstained, 187 not voted.

FOR
FOR: 80,242,958AGAINST: 4,676ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Alexander Hardy” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,162,7833 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,1690 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Athena Countouriotis

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 162,326,065AGAINST: 1,823,399

Prior year: 99.0% for (May 20, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Athena Countouriotis

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Athena Countouriotis”): 162,326,065 for, 1,823,399 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 80,242,956 for, 4,678 against, 30,100 abstained, 187 not voted.

FOR
FOR: 80,242,956AGAINST: 4,678ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Athena Countouriotis” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,162,7815 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,1690 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Barbara W. Bodem

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 162,832,241AGAINST: 796,989

Prior year: 99.4% for (May 20, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Barbara W. Bodem

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 162,832,241 for, 796,989 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 80,242,957 for, 4,674 against, 30,101 abstained, 187 not voted.

FOR
FOR: 80,242,957AGAINST: 4,674ABSTAIN: 30,101NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Barbara W. Bodem” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,162,7821 10For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,1690 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Elizabeth M. Anderson

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 152,826,855AGAINST: 11,325,400

Prior year: 96.8% for (May 20, 2025 meeting) ▼ 3.7 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Elizabeth M. Anderson

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 152,826,855 for, 11,325,400 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 77,587,955 for, 2,659,678 against, 30,100 abstained, 187 not voted.

FOR
FOR: 77,587,955AGAINST: 2,659,678ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Elizabeth M. Anderson” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,141,81520,971 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,944,7894,380 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional01,284,559 00Against
AQR763,3980 00For
Thrivent703,0360 00For
TIAA0594,303 00Against
JANUS INVESTMENT FUND504,8800 00For
Jackson National415,04732,118 00Mixed
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock91,582150,338 00Mixed
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Ian T. Clark

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 144,380,101AGAINST: 19,160,530
Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Ian T. Clark

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Ian T. Clark”): 144,380,101 for, 19,160,530 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 77,983,205 for, 2,264,427 against, 30,101 abstained, 187 not voted.

FOR
FOR: 77,983,205AGAINST: 2,264,427ABSTAIN: 30,101NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Ian T. Clark” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard27,413,765749,019 10For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,367,57220,391 00For
Capital Group3,361,2860 00For
State Street2,944,6454,524 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable69,448207,762 00Mixed
Russell Investments0249,772 00Against
John Hancock241,9200 00For
DWS0230,791 00Against
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide182,65510,836 00Mixed

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Mark J. Enyedy

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 161,113,325AGAINST: 3,032,040

Prior year: 99.2% for (May 20, 2025 meeting) ▼ 1.0 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Mark J. Enyedy

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 161,113,325 for, 3,032,040 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 79,485,343 for, 762,290 against, 30,100 abstained, 187 not voted.

FOR
FOR: 79,485,343AGAINST: 762,290ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Mark J. Enyedy” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,151,15211,634 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,1690 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA0594,303 00Against
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Maykin Ho

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 160,849,437AGAINST: 3,300,117

Prior year: 98.9% for (May 20, 2025 meeting) ▼ 0.9 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Maykin Ho

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Maykin Ho”): 160,849,437 for, 3,300,117 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 79,854,217 for, 393,416 against, 30,100 abstained, 187 not voted.

FOR
FOR: 79,854,217AGAINST: 393,416ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Maykin Ho” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,141,83520,951 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,944,7894,380 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Robert J. Hombach

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 160,262,501AGAINST: 3,342,524

Prior year: 98.4% for (May 20, 2025 meeting) ▼ 0.4 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Robert J. Hombach

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Robert J. Hombach”): 160,262,501 for, 3,342,524 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 79,854,217 for, 393,414 against, 30,101 abstained, 187 not voted.

FOR
FOR: 79,854,217AGAINST: 393,414ABSTAIN: 30,101NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Robert J. Hombach” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,141,83520,949 10For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,944,7894,380 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Timothy P. Walbert

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 158,544,683AGAINST: 5,554,116

Prior year: 99.6% for (May 20, 2025 meeting) ▼ 3.0 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Timothy P. Walbert

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 158,544,683 for, 5,554,116 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 78,377,400 for, 1,870,232 against, 30,100 abstained, 187 not voted.

FOR
FOR: 78,377,400AGAINST: 1,870,232ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Timothy P. Walbert” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,162,77014 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,1690 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional01,284,559 00Against
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National415,04732,118 00Mixed
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock91,582150,338 00Mixed
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Elect Director: Willard Dere

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 161,112,606AGAINST: 2,973,541

Prior year: 98.5% for (May 20, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: Election of Directors: Willard Dere

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Willard Dere”): 161,112,606 for, 2,973,541 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 79,854,218 for, 393,415 against, 30,100 abstained, 187 not voted.

FOR
FOR: 79,854,218AGAINST: 393,415ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “Election of Directors: Willard Dere” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,141,83620,950 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,944,7894,380 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment

Official resultCOMPENSATIONReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 158,561,867AGAINST: 5,480,380

Prior year: 95.3% for (May 20, 2025 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 133 asset managers

Description as filed by funds: To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.

BioMarin Pharmaceutical Inc.’s own tally for this item (“4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes”): 158,561,867 for, 5,480,380 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved the Plan Amendment.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 133 asset managers below reported 79,958,867 for, 184,700 against, 30,100 abstained, 2,907 not voted.

FOR
FOR: 79,958,867AGAINST: 184,700ABSTAIN: 30,100NOT VOTED: 2,907
Largest asset managers voting on “To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,162,77411 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,08485 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 133 asset managers. All 133 are in the interactive database (link above).

Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 12 wordings of this item as funds reported it.

87% Approved · of votes cast

FOR 87%
FOR: 142,742,800AGAINST: 21,287,767

Prior year: 93.8% for (May 20, 2025 meeting) ▼ 6.8 pts

Details: description as filed, official tally, votes by 507 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

BioMarin Pharmaceutical Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 142,742,800 for, 21,287,767 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 123 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard27,413,761749,025 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,194,877193,086 00For
Capital Group3,361,2860 00For
State Street2,944,6454,524 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,203449 00For
Dimensional01,284,559 00Against
AQR763,3980 00For
Thrivent703,0360 00For
TIAA0594,303 00Against
JANUS INVESTMENT FUND504,8800 00For
Jackson National327,125120,040 00Mixed
Columbia Threadneedle361,3410 00For
SEI0327,820 00Against
Equitable277,2100 00For
Russell Investments0249,772 00Against
John Hancock91,582150,338 00Mixed
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust13,369207,900 00Mixed
AIG/SunAmerica212,1800 00For
Nationwide93,135100,356 00Mixed

Fund voting reports, all 123 managers: 75,111,556 for, 5,126,000 against, 34,773 abstained, 187 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 416 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
PRIMECAP MANAGEMENT CO/CA/13,864,1950 00For
Dodge & Cox13,772,4590 00For
State Street6,918,93252,659 00For
BlackRock6,952,89417,633 00For
VIKING GLOBAL INVESTORS LP6,945,7990 00For
Fidelity3,800,2870 00For
GEODE CAPITAL MANAGEMENT, LLC3,788,8540 00For
AQR3,583,7050 00For
Capital Research Global Investors3,496,8780 00For
Vestal Point Capital, LP2,620,1480 00For
Invesco2,095,5930 00For
Charles Schwab1,671,989449 00For
Citadel1,604,1590 00For
Vanguard1,518,5400 00For
Northern Trust1,368,46617,542 00For
DnB Asset Management AS1,236,0110 00For
Janus Henderson1,198,1020 00For
PICTET ASSET MANAGEMENT SA1,180,6170 00For
MELLON INVESTMENTS Corp1,180,1330 00For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC0864,198 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.851,5560 00For
Dimensional0826,266 00Against
Wellington0803,958 00Against
Swedbank Robur Fonder AB0752,187 00Against
River Road Asset Management, LLC0740,265 00Against

Institutional-manager reports, all 416 managers: 94,170,897 for, 14,625,404 against, 14,774 abstained, 2,600 not voted, 52 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 170,867,335AGAINST: 4,850,526

Prior year: 95.8% for (May 20, 2025 meeting) ▲ 1.5 pts

Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.

BioMarin Pharmaceutical Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 170,867,335 for, 4,850,526 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2026.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 123 asset managers below reported 80,224,219 for, 19,014 against, 30,100 abstained, 187 not voted.

FOR
FOR: 80,224,219AGAINST: 19,014ABSTAIN: 30,100NOT VOTED: 187
Largest asset managers voting on “To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for t” at BioMarin Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard28,151,14711,639 00For
BlackRock11,688,3630 00For
Dodge & Cox11,483,3250 00For
Fidelity6,387,9630 00For
Capital Group3,361,2860 00For
State Street2,949,025144 00For
PRIMECAP Odyssey Funds2,332,3410 00For
First Trust1,592,7700 00For
Charles Schwab1,564,6520 00For
Dimensional1,284,5590 00For
AQR763,3980 00For
Thrivent703,0360 00For
TIAA594,3030 00For
JANUS INVESTMENT FUND504,8800 00For
Jackson National447,1650 00For
Columbia Threadneedle361,3410 00For
SEI327,8200 00For
Equitable277,2100 00For
Russell Investments249,7720 00For
John Hancock241,9200 00For
DWS230,7910 00For
Invesco222,5870 00For
Bridge Builder Trust221,2690 00For
AIG/SunAmerica212,1800 00For
Nationwide193,4910 00For

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 20, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest BioMarin Pharmaceutical Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 193,268,870 shares outstanding at the time of that meeting.

Fund voting reports: top BioMarin Pharmaceutical Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 14.57%
2BlackRock 6.05%
3Dodge & Cox 5.94%
4Fidelity 3.31%
5Capital Group 1.74%
6State Street 1.53%
7PRIMECAP Odyssey Funds 1.21%
8First Trust 0.82%
9Charles Schwab 0.81%
10Dimensional 0.66%
Institutional-manager reports: top BioMarin Pharmaceutical Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2025-2026
#Asset manager % of shares outstanding
1PRIMECAP MANAGEMENT CO/CA/ 7.17%
2Dodge & Cox 7.13%
3State Street 3.61%
4BlackRock 3.61%
5VIKING GLOBAL INVESTORS LP 3.59%
6Fidelity 1.97%
7GEODE CAPITAL MANAGEMENT, LLC 1.96%
8AQR 1.85%
9Capital Research Global Investors 1.81%
10Vestal Point Capital, LP 1.36%

Reported BioMarin Pharmaceutical Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BioMarin Pharmaceutical Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
The Vanguard Group18,992,533 9.83%Proxy statement (DEF 14A), table as of April 7, 2026
BlackRock, Inc.17,560,751 9.09%Schedule 13G, filed January 21, 2026
PRIMECAP Management Company15,795,383 8.17%Proxy statement (DEF 14A), table as of April 7, 2026
Dodge & Cox13,994,063 7.24%Proxy statement (DEF 14A), table as of April 7, 2026
State Street7,295,079 3.77%Form 13F, quarter ended March 31, 2026
Citadel Advisors4,697,834 2.43%Form 13F, quarter ended March 31, 2026
Geode Capital3,819,441 1.98%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors3,802,930 1.97%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)3,567,031 1.85%Form 13F, quarter ended March 31, 2026
Morgan Stanley2,315,620 1.20%Form 13F, quarter ended March 31, 2026

Percentages above are of 193,268,870 shares outstanding, as reported by BioMarin Pharmaceutical Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BioMarin Pharmaceutical Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 510 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 7,512 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BioMarin Pharmaceutical Inc.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BioMarin Pharmaceutical Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioMarin Pharmaceutical Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BioMarin Pharmaceutical Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “BioMarin Pharmaceutical (BMRN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biomarin-pharmaceutical-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.